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A  PROSPECTIVE, RANDOMIZED, OPEN LABEL, COMPARATIVE STUDY OF ATORVASTATIN 
ALONE AND ATORVASTATIN WITH LYCOPENE IN PATIENTS WITH HYPERLIPIDAEMIA 
ATTENDING TERTIARY CARE HOSPITAL 
          Dr. Suganeshwari S, Dr. Kalaiselvi B, Dr. Nandini R. 
ABSTRACT 
AIM: 
1. To compare the efficacy and tolerability of Atorvastatin alone and Atorvastatin with Lycopene  in the      
    management of Hyperlipidaemia. 
METHODOLOGY 
 
    This was an open label, comparative, randomized, prospective study. This study included 100 
patients with Hyperlipidaemia, who were randomized into two groups of 50 each. One group received 
T.Atorvastatin 10mg/day and other group received T.Atorvastatin 10mg/day with T.Lycopene 15mg/day 
for 8 weeks. They received routine follow-up fortnightly for 8weeks. Lipid profile was assessed at 
baseline and at the end of the study.  
 
RESULTS 
  The baseline characteristics were similar in both the study groups. On comparing the groups at the end 
of 8weeks there was a statistically significant reduction in Total cholesterol and LDL cholesterol levels. 
  (TC - p <0.001; LDL- p <0.004). The hematological, hepatic and renal function test did not show any 
significant change when compared to baseline. Minimal adverse effects were observed in both the study 
groups. 
 
CONCLUSION 
1. From this study, we can conclude that Atorvastatin with Lycopene was effective in reducing  the     
    lipid levels.  
    2.  The combination was well tolerated. 
 
KEY WORDS 
   Atorvastatin, Lycopene. 
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INTRODUCTION 
Cardiovascular diseases are one of the most common group of diseases causing 
increased pre-mature mortality and morbidity in both developing and developed 
countries. Atherosclerosis affecting the arterial vessel wall and the resulting thrombosis 
are the main pathogenic processes causing increased risk of cardiovascular diseases.   
The main clinical entities of CVD are coronary artery disease, ischaemic stroke, 
congestive heart failure, hypertension, peripheral arterial disease, and congenital heart 
disease
1
.
 
  
Various epidemiological factors have been attributed as risk factors for CHD 
(Coronary Heart Disease). Age, male individuals, hyperlipidemia, Type II diabetes 
mellitus, and smoking are some of the important risk factors for CHD.
  
Hypercholesterolemia, is the term comprising elevated low-density lipoprotein (LDL) 
levels, and low high-density lipoprotein (HDL) levels and are unequivocally linked to 
increased risk for coronary heart disease and cerebrovascular disease. The LDL 
cholesterol levels are the primary target
2
. Thus, Hypercholesterolemia is a significant 
modifiable cardiovascular risk factor, and the risk is directly proportional to the degree 
of cholesterol elevation. 
  The most common cause of death is Coronary Heart Disease worldwide. In 
India, approximately 46.9 million patients presented with cardiovascular disease in 2010. 
An estimated death of 2.3 million people was recorded during 2008. A drastic increase of 
23.3 million deaths is expected in the year 2030 due to cardiovascular disease
3
. 
According to World health organization, CHD is considered as our modern 
EPIDEMIC i.e., a disease that affects population not an unavoidable attribute of aging.  
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In India, the burden of Ischaemic Heart Disease is increasing every year, because 
of increased exposure to risk factors like unhealthy diet, lifestyle modification, smoking, 
obesity etc. By the year 2015, it may predominate as the single most important cause of 
death
4
.  
The stress induced lifestyle is most common in our day to day activities which 
also more prone for causing increased oxidative stress. The release of reactive oxygen 
species is increased due to oxidative stress which contributes as the aetiology of the 
several chronic diseases
5
. 
The endogenous antioxidants are depleted to overcome the increased oxidative 
stress. Thus the importance of the antioxidant rich vitamins like Vitamin A, E, C in the 
prevention of these chronic heart diseases is being stressed nowadays. Nutrients rich in 
antioxidants are modestly attributed to decrease the tissue damage which prevents the 
atherosclerotic process
6
.   
Apart from vitamins, certain antioxidants are being present in the plants which 
are most commonly used. Among natural antioxidant, lycopene is an extract obtained 
from tomatoes which is one of the most potent and most effective antioxidant. It helps in 
preventing the oxidation of lipids with its single-oxygen quenching ability two times 
more potent than β-carotene and 10 times than α-tocopherol7.  
It has a role in altering the metabolism and oxidation of lipids which predispose 
to the formation of atherosclerosis.
 
Lycopene shows 37% decrease in synthesis of cholesterol in J-774A.1 
macrophage cell line, and it also augment the activity of macrophage LDL receptors. 
Macrophage enrichment with lycopene results in the suppression of cellular cholesterol 
11 
 
synthesis by inhibiting the enzyme, HMG-CoA reductase. This effect leads to increased 
clearance of LDL from the plasma and due to this effect lycopene is being recognized as 
hypolipidemic agent
8
. 
Hence, the present study was planned to assess the efficacy of Lycopene in 
addition to atorvastatin in reducing total cholesterol and LDL-C and also to compare 
with that of atorvastatin when used alone.  
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REVIEW OF LITERATURE 
Cardiovascular diseases (CVD) are one of the leading causes of morbidity and 
mortality in the world. Increase in cholesterol level is a predominant risk factor for 
atherosclerosis and associated coronary and cerebro-vascular diseases.  
The presence of high level of cholesterol in the blood is termed as 
Hypercholesterolemia. Higher the level of low density lipoprotein cholesterol, higher 
risk for atherogenesis. The increased level of LDL occurs due to inadequate removal of 
cholesterol from macrophages by HDL cholesterol. These increased levels of LDL-C are 
oxidized by reactive oxygen species. The oxidised LDL-C are further scavenged by the 
macrophages which results in foam cell formation and accumulation of numerous 
adhesion factors, monocytes and neutrophils on the vascular lumen. The resultant 
atherosclerosis is the predisposing factor for various cardiovascular diseases which 
affects the quality of life. 
So, to lead a healthy life a balance in cholesterol homeostasis is important which 
can be achieved by a gene network involved in cholesterol synthesis, absorption, 
metabolism and elimination. 
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LIPID METABOLISM 
Lipid metabolism is a process that involves synthesis and degradation of lipids or 
cholesterol. Lipids are heterogeneous group of compounds, including fats, oils, steroids, 
and waxes, which are related mainly by their physical properties.  
They are water insoluble but it is carried within the protein particles called 
lipoproteins in the blood plasma. They are stored as a source of energy production. 
Types of lipids: 
1. Simple  
2. Complex / Compound  
3. Other (Neutral) lipids 
1. Simple lipids 
These are esters of fatty acids with various alcohols. They are,  
i. Lauric acid and palmitic acids are saturated fatty acids which have 
sizeable effect on increasing blood cholesterol level. Most hydrogenated 
vegetable oils like ―Dalda‖ have saturated fatty acids. 
ii. Oleic acid and palmitoleic acids are monounsaturated fatty acids having 
one double bond in their structure. They are mostly present in olives and 
nuts. They are useful in decreasing LDL and VLDL cholesterol levels 
when compared to saturated fatty acids. 
iii. Linolenic acid and arachidonic acids are polyunsaturated fatty acids. The 
structure comprises of 2 or more double bonds. They have a lipid 
lowering effect. They are abundant in safflower oil, corn oil, and fish oil. 
15 
 
iv. Elaidic acid is unsaturated fatty acid which is generated during 
hydrogenation of polyunsaturated fatty acids and monounsaturated fatty 
acids. These are present in some commercial vegetable oils. They are 
harmful because of their increasing LDL cholesterol and lowering HDL 
cholesterol levels. 
 
2. Complex / Compound lipids 
     They are fatty acids esters containing groups like phosphoric acid residue, 
spingosine in their structure. e.g. phospholipids and sulfolipids. 
 
3. Other lipids (Neutral lipids) 
     The non-polar lipids include Cholesterol (CH), Triglycerides (TGs), and 
Cholesterol esters (CE). Triglycerides are glycerol with its structure containing 
all three hydroxyl groups linked to fatty acids. Cholesterol is said to be sterol 
chemically but not a fat. They are transported as solubilised form in the blood 
stream with the help of lipoproteins
9
.
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LIPOPROTEIN METABOLISM 
The biochemical assembly of lipids and proteins are called lipoproteins. These 
are important cellular constituents in the cell membrane and mitochondria. Lipoproteins 
are essential for the transport of cholesterol and triglycerides. Lipoproteins play an 
important role in the dietary cholesterol absorption and transport of lipids from the 
intestine as chylomicrons and from the liver as very low density lipoproteins (VLDL- C). 
These are transported to most of the tissues for oxidation and for storage in adipose 
tissue
10
.
 
   The structure of lipoprotein is made up of a hydrophobic core containing 
triglycerides and cholesteryl esters which are surrounded by a hydrophilic lipid 
containing phospholipids and unesterified cholesterol. 
      
Structure of Lipoprotein              
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Based on their relative density and diameter, the lipoproteins are classified into five 
types. It is described from larger and less dense to smaller and denser. They are 
considered as larger and less dense when the fat to protein ratio is increased.  
1. The lipoprotein with greater diameter and lower density is known as 
Chylomicrons, which are derived from absorption of triacylglycerol and other 
lipids from the intestine. 
2. Very low density lipoproteins (VLDL, or pre-ß-lipoproteins) with lower 
diameter and higher density than chylomicrons, which are derived from the liver 
for the transport of newly synthesized triacylglycerol. 
3. Intermediate density lipoprotein (IDL) is a lipoprotein with lower diameter and 
higher density than VLDL. They are usually not measurable in blood during 
fasting. 
Major classes of Lipoprotein particles 
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4. Low-density lipoproteins (LDL, or ß lipoproteins), represents a final stage in the 
catabolism of VLDL. They are termed as ―bad cholesterol‖ due to increased 
progression of atherosclerosis. 
5. High-density lipoproteins (HDL, or α-lipoproteins), with highest density and 
lower diameter involved in reverse cholesterol transport carrying fat molecules 
from the tissue back to the liver. They are termed as ―good cholesterol‖ due to 
their protective effect from atherogenesis. 
           
 
APOLIPOPROTEINS 
Apolipoproteins are proteins which bind with lipids to form lipoproteins.  
The main functions of apolipoproteins are 
 They form the structure of lipoprotein eg, apo B. 
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 They act as enzyme cofactors or enzyme inhibitors. 
  Eg,  
            C-II and A-I are enzyme cofactors. 
 Lipoprotein lipase – C II 
 Lecithin:cholesterol acyltransferase – A I 
A-II and C-III are enzyme inhibitors. 
 Lipoprotein lipase - Apo A-II and C-III 
 They act as ligands  
     Eg,  
 LDL receptor - Apo B-100 and apo E 
 LDL receptor related protein - Apo E 
 HDL receptor - Apo A-I 
 
EXOGENOUS PATHWAY OF LIPIDS  
       Fat-soluble vitamins, dietary cholesterol and fatty acids are absorbed in 
the proximal part of the small intestine. Inside the intestinal lumen, lipases hydrolyse 
the dietary triglycerides and emulsify with bile acids to form micelles. 
     In the enterocyte, by the addition of a free fatty acid the cholesterol 
esterification occur which results in the formation of cholesteryl esters. Incorporation 
of triglycerides with fatty acids containing more than 12 carbons atoms are packed 
with apo-B48, cholesteryl esters, retinyl esters, phospholipids, and cholesterol 
resulting in the formation of chylomicrons.  
The newly secreted chylomicrons are called nascent chylomicrons which are 
absorbed into the intestinal lymph and carried directly through the thoracic duct to 
20 
 
the blood stream. They are transported to the peripheral tissues before entering the 
liver. 
     In heart, skeletal muscle and adipose tissue these nascent chylomicrons 
are attached to the lipoprotein lipase anchored by a protein called 
phosphatidylinositol-anchored protein, GPIHBP1. These reactions occur mainly on 
the endothelial surface of the capillaries. They are hydrolysed by the lipoprotein 
lipase and the free fatty acids are released. HDL transfers the apo C-II to the 
chylomicron that acts as a cofactor for lipoprotein lipase.  
The released free fatty acids are taken up by heart and skeletal muscles which are 
oxidized to generate energy. They can also be re-esterified and stored as triglyceride. 
Some of the free fatty acids released will enter into the hepatocytes by binding with 
the plasma protein like albumin.  
Due to hydrolysation of its hydrophobic core the resultant chylomicrons 
progressively decrease in size. The hydrophilic lipids like cholesterol, phospholipids 
and the protein moiety apolipoproteins on the particle surface are transferred to HDL. 
These result in the formation of a chylomicron remnant which is about half the 
diameter of nascent chylomicron.   
 The chylomicron remnants are mainly made up of cholesterol and cholesteryl 
esters. These remnants are rapidly taken up by the liver from the circulation where 
apo-E act as a ligand. 
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ENDOGENOUS PATHWAY OF LIPIDS- HEPATIC LIPIDS 
     The endogenous transport of cholesterol mainly involves  
 The liver which secretes apo-B lipoproteins and  
 The peripheral tissues where the triglycerides particles are metabolized. 
     
The VLDL particles resemble chylomicrons in protein composition, where the 
apo-B48 is replaced by apoB-100. They have the higher ratio of cholesterol and 
triglycerides.  
The triglycerides present in the very low density lipoprotein are derived mainly 
from the esterification of long-chain fatty acids in the liver. The process of 
combining the hepatic triglycerides with the other major components of the nascent 
VLDL particle like apoB-100, phospholipids and cholesteryl esters are acquired by 
the action of the enzyme protein called microsomal triglyceride transfer protein 
(MTP). 
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Diagram shows both exogenous and endogenous pathway 
 
    
In the plasma, HDL transfers the apo-E and the C series of apolipoproteins to the 
VLDL particle. In the heart, skeletal muscle and adipose tissue the triglycerides of 
the VLDL particle are hydrolysed by the lipoprotein lipase enzyme similar to the 
process occurring in to the chylomicron. This results in the formation of VLDL 
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remnants which dissociated from the lipoprotein lipase. Then these remnants are 
called as IDL (intermediate density lipoprotein).  
    IDL contain almost same amounts of triglyceride and cholesterol. 40-60% of IDL 
particle are removed by the liver through endocytosis by binding to apo-E and apoB-
100. The remaining IDL is remodeled by hepatic lipase enzyme to form LDL.  
In this process most of the triglycerides are hydrolysed and results in the 
formation of LDL which carries apoB-100. In most of the individuals the 
concentration of plasma cholesterol is equivalent to the amount of cholesterol present 
in the LDL particle. In the liver, circulating LDL cholesterol of about 70% is cleared 
by LDL receptor-mediated endocytosis. 
Receptor-mediated endocytosis of low density lipoprotein
11,12
: 
    1. In the non-hepatic cells, apo B-100 over the surface of a LDL particle binds to a 
specific receptor protein called clathrin. The receptors for LDL are localized in a 
specialized region called coated pits containing the receptor protein. 
   2. The LDL- receptor complex is engulfed by a process called endocytosis resulting in 
the formation of an endocytic vesicle. 
   3. The endocytic vesicle later fuse with lysosomes which carries a wide array of 
degradative enzymes. The protein and cholesteryl ester of low density lipoprotein are 
hydrolysed by lysosomal enzyme, lipase. The free amino acids are released from the 
protein component. The cholesteryl esters present in the LDL particle are hydrolyzed 
by a lysosomal acid lipase. The LDL receptor itself usually returns unmodified to the 
plasma membrane. The turn- around time for a receptor is about 10 minutes. In its 
lifetime of about a day, it may bring many LDL particles into the cell. 
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Receptor mediated endocytosis                 
   
4. The un-esterified cholesterol can be used for membrane biosynthesis and also it 
can be re-esterified and stored inside the cell. In fact, free cholesterol activates 
acyl CoA: cholesterol acyltransferase (ACAT), the enzyme catalyzing this 
reaction.  
5.  Oleate and palmitoleate are the monounsaturated fatty acids present in the re-
esterified cholesterol while the cholesterol esters in LDL contain linoleate, a 
polyunsaturated fatty acid. High concentrations of unesterified cholesterol disrupt 
the integrity of cell membranes.  
25 
 
6. The synthesis of LDL receptor is itself subjected to feedback regulation. When 
cholesterol is abundant inside the cell, synthesis of new LDL receptors does not 
occurs and thus the uptake of further cholesterol from plasma is inhibited. 
LDL-C ROLE IN LIPID METABOLISM 
   The metabolism of cholesterol is regulated precisely to prevent the formation of 
atherosclerosis. Since the major carrier of cholesterol in the blood is low density 
lipoprotein, it plays a major role in the formation of atherosclerosis. The main role of 
LDL-C is to transport the cholesterol to peripheral tissues. 
Control of cholesterol synthesis in liver 
  In the liver, low density lipoproteins controls the synthesis of cholesterol by 
reducing the effect of 3- hydroxy-3-methylglutaryl CoA reductase enzyme. 
Control of cholesterol synthesis in non-hepatic cells 
 The Low density lipoproteins are the primary source of cholesterol in the non-
hepatic cells. In most cases of familial hypercholesterolemia, the major molecular defect 
is a deficiency or absence in LDL receptor. Thus the increased level of LDL-C is 
deposited in various tissues. Atherosclerotic lesion contains mainly the oxidized lipids 
derived from the LDL-C.  
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ROLE OF HDL 
  Apolipoproteins of high density lipoproteins are secreted by the intestine and 
liver. High density lipoprotein derives cholesterol from the surface monolayers of 
chylomicrons and VLDL. It also acquires cholesterol from the peripheral tissues, which 
protects the cells to maintain cholesterol homeostasis. 
    From the cell membrane the free cholesterol is mainly transported by a 
transporter called ABCA1, which is acquired by a small particle termed prebeta-1 HDL. 
The mature HDL particle is formed by the esterification of the resultant nascent HDL by 
lecithin:cholesterol acyl tranferase (LCAT). 
 
Reverse cholesterol transport 
 
The free cholesterol expelled from the macrophages by means by an ABCA1 
transporter, which results in the formation of the mature HDL particles. The cholesteryl 
esters from the mature HDL particle are transferred to chylomicrons remnants, VLDL, 
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IDL and LDL, by means of a transfer protein called Cholesteryl ester transfer protein 
(CETP).  
 The transferred cholesteryl ester from the HDL particle is finally taken up by the 
liver via two processes 
 Endocytosis.  
 Docking receptor or scavenger receptor, SR-B113.  
The process involved in the HDL metabolism is called reverse cholesterol 
transport mechanism. 
PROTECTIVE ROLE OF HDL 
Protective role of HDL-C 
        
 
1. Has an anti-inflammatory property. 
2. Act as an anti-oxidant by improving endothelial function through stimulating the 
endothelial nitric oxide production. 
3. Inhibition of cell adhesion molecules expression such as vascular cell adhesion 
molecule -1 (VCAM-1), E-Selectin, intercellular adhesion molecule-1, and also 
the accumulation of inflammatory infiltrates in the vessel wall. 
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HYPERLIPIDEMIA 
DEFINITION OF HYPERLIPIDEMIA 
Dyslipidemia refers to the alteration of one or many of the lipoproteins which 
may be an elevation of triglycerides or low density lipoproteins cholesterol, or decrease 
in high-density lipoprotein cholesterol, while lipid elevation alone is termed as 
‗Hyperlipidemia‘14. 
Various terms, 
 Hyperlipidemia – increase in lipid levels, 
 Hypercholesterolemia – increase in cholesterol levels, 
 Hyperlipoproteinemia – increase in lipoprotein levels. 
HYPERLIPOPROTEINEMIA- CAUSES
15 
1. Environmental factors 
2. Genetic factors 
3. Secondary causes 
1. Environmental factors 
        Dietary factors and obesity. 
2. Genetic factors 
    Occur due to single gene or multiple gene defects 
 
CLASSIFICATION OF HYPERLIPOPROTEINEMIA - FREDRICKSON-LEVY-
LEES 
16 
Familial Hyperchylomicronaemia – Type I 
 This type usually presents as massive fasting hyperchylomicronemia. There is 
rise in serum triglyceride levels even after normal fat intake in diet. 
 Lipoprotein lipase or normal apolipoprotein C-II (rare) deficiency is the cause. 
29 
 
 Type I usually does not increase risk of coronary heart disease. 
 No drug therapy is effective but low fat diet should be followed. 
Familial Hyperchylomicronaemia – Type II A 
 LDL-C degradation is halted causing rise in LDL-C with normal VLDL-C levels. 
Serum cholesterol level is raised, triglyceride levels are normal. 
 Defects in the synthesis or processing of LDL-C receptors are the causes. 
 Risk of Ischaemic heart disease is highly increased. 
 Proper diet can be an effective treatment. 
 In heterozygotes: Drug therapy like cholestyramine, statin or niacin. 
Familial combined or mixed Hyperlipidemia – Type II B 
 Similar to IIA, but here VLDL-C is increased, resulting in elevated serum 
triglycerides and cholesterol levels. 
 Overproduction of VLDL-C in the liver is the cause and relatively common. 
 Treatment: Diet modulation and drugs. Treatment is similar to Type IIA 
treatment. 
Familial dysbetalipoproteinemia – Type III 
 Mutation of apo E cause increased production or under utilization of IDL 
cholesterol which results in increased serum levels. These also cause increased 
triglycerides and cholesterol levels. 
 Causes xanthomas and acceleration of vascular disease in middle aged patients. 
 Treatment: Diet modulation and drugs niacin and fenofibrate or statin. 
Familial Hypertriglyceridaemia – Type IV 
 Increased VLDL-C levels, normal or decreased LDL-C levels, normal to 
increased cholesterol, highly increased circulating triglyceride levels are the 
features. 
30 
 
 The increased VLDL cholesterol level is due to overproduction and/or impaired 
removal of serum VLDL-C triglycerides. 
 It is relative common disease with few clinical manifestations apart from 
accelerated ischaemic heart disease like obesity, diabetes and hyperuricaemia. 
 Treated with diet modulation and drug therapy like niacin and/or fenofibrate. 
Familial mixed Hypertriglyceridemia – Type V 
 Raised VLDL-C and chylomicron levels, normal or reduced LDL-C causing 
increased cholesterol and greatly increased triglyceride levels. 
 The increased levels are due to either over production or reduced clearance of 
VLDL-C and chylomicrons due to a genetic defect. 
 Affected patients are adults with obesity and diabetes. 
 Treatment: Diet, drugs includes niacin, and/or fenofibrate. 
 
 SECONDARY CAUSES 
17 
 Diabetes mellitus   Chronic renal failure 
 Hypothyroidism   Glycogen storage disease 
 Lipodystrophy    Pregnancy  
 Stress     Sepsis 
 Alcohol excess    Acute hepatitis 
 Anti-hypertensive drugs,  diuretics 
 Glucocorticoid treatment  Protease inhibitor therapy 
 Nephritic syndrome   Obstructive liver disease   
 Acute intermittent porphyria  Anorexia nervosa 
 Cholestasis     
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HYPERLIPIDEMIA - RISK FACTOR FOR ATHEROSCLEROSIS. 
The mechanism by which hyperlipidemia contributed to atherogenesis includes: 
1.  Accumulation of lipoproteins within the tunica intima of arterial wall mainly at 
the site of increased permeability. 
2. An increased cholesterol level directly impairs the function of endothelium by 
increased production of oxygen free radicals. The impaired endothelium will 
cause decreased release of endothelial relaxing factor nitric oxide. 
3. Low density lipoproteins are oxidized by the generated free radicals by the 
macrophages and endothelial cells results in formation of the oxidized LDL-
cholesterol. 
4. The resultant oxidized LDL cholesterol is readily ingested by the macrophages 
through scavenger receptor resulting in the formation of foam cells. 
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Role of Oxidized LDL-C in atherosclerosis 
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ATHEROSCLEROSIS 
Atherosclerosis mainly involves the intima of the large and medium sized 
muscular arteries and is composed of fibrofatty cap (smooth muscle cells, lymphocyte, 
foam cell, collagen, macrophage, neovascularisation, proteoglycans, elastin) and necrotic 
center (foam cells, cell debris, calcium, cholesterol crystal)
18
. 
The term atheroma is derived from the greek word ―athera‖ means lump of gruel. 
It is a chronic inflammatory response resulting from endothelial injury to the arterial wall 
causing invasion of leukocytes and formation of oxidized lipoproteins. It is commonly 
referred to as ―hardening‖ or ―furring‖ of arteries. 
Atherosclerosis and its relevant vascular events involving coronary artery causing 
cardiovascular disease (CVD) and cerebral artery causing stroke and periphery artery 
causing peripheral arterial disease (PAD) have become one of the leading cause of 
disability and mortality
19
. 
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Atherosclerosis 
 
 
 Pathogenesis of atherosclerosis
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Pathogenesis of atherosclerosis
20 
Chronic injury to endothelial wall 
 
Increased permeability, adhesion of leukocytes, and thrombosis 
 
Lipoprotein accumulation (LDL and its oxidized forms) in the vessel wall 
 
Adhesion of monocytes and migration into intima of vessel 
 
Formation of macrophages and foam cells 
 
Release of platelet adhesion factor from activated platelets, macrophages  
 
 Recruitment and proliferation of smooth muscle cell 
 
Lipid accumulation both extracellular and intracellular (macrophages and SMCs) 
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RISK FACTOR FOR ATHEROSCLEROSIS 
Major Non Modifiable Lesser, Uncertain  
Elderly Obesity 
Male sex Physical Inactivity 
Family history High Carbohydrate diet 
Genetic abnormalities Stress (Type A personality) 
 Post menopausal  
 Estrogen deficiency 
 Lipoprotein [LP(a)] 
 Hardened unsaturated fat intake 
Potentially controllable  
Hyperlipidemia  
Hypertension Chlamydia pneumonia 
Cigarette smoking  
Diabetes  
C-reactive protein  
 
Hyperlipidemia is one of the potentially controllable risk factors in causing 
atherosclerosis. 
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TREATMENT GUIDELINES FOR OPTIMAL PLASMA LIPID LEVELS:
21 
Lipid Levels classification: 
        Total cholesterol: 
  
 
HDL cholesterol: 
       
 
         LDL cholesterol: 
 
   
 
Desirable less than 200 mg/dl 
Borderline high 200-239 mg/dl 
High more than equal to 240 mg/dl 
Low less than 40 mg/dl (50 in women) 
High More than 60 mg/dl 
Optimal for very high risk Less than 70 mg/dl 
Optimal Less than100 mg/dl 
Near optimal 100-129 mg/dl 
Borderline high 130-159 mg/dl 
High 160-189 mg/dl 
Very High ≥190 mg/dl 
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Triglycerides 
 
MANAGEMENT OF HYPERLIPIDEMIA 
The treatment includes: 
1. Modification of diet 
2. Physical exercise 
3. Avoidance of associated risk factors.  
4. Medical management of Hyperlipidemia 
 
1. MODIFICATION OF DIET 
The primary treatment of hyperlipidemia is dietary modification. Drugs are added 
later to augment treatment. The ―heart-healthy‖ diet is a food which contains low 
saturated fat. These provide a sufficient energy for the growth and maintain an adequate 
weight of an individual. 
The specific dietary interventions are 
(a) Decreased intake of saturated fat:  
Decreased intake of saturated fat has the greatest impact in reducing LDL 
cholesterol levels in the blood. The foods containing saturated fats are 
hydrogenated peanut butters, partially hydrogenated oils and fats, commercial 
fried food, commercial bakery products and animal products containing fat. 
 
Normal Less than 150 mg/dl 
Borderline high 150-199 mg/dl 
High 200-499 mg/dl 
Very High ≥ 500 mg/dl 
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(b) Low intake of trans-fatty acids:  
    Foods rich in trans-fatty acids are considered to increase the level low density 
lipoprotein cholesterol and it also decreases HDL cholesterol levels. 
 
(c) Decreased intake of dietary cholesterol:  
The intake of dietary cholesterol varies from individual to individual. The 
decreased intake of cholesterol diet helps in reduction of LDL-C levels. The 
hyperglycemic patients are more sensitive to increased dietary cholesterol intake, 
which are rich in animal fat. 
 
(d) Appropriate balance of fatty acid composition in diet:  
 More consumption of monounsaturated and polyunsaturated fatty acids 
are better substitutes for saturated fats in lowering the LDL cholesterol levels. 
 
(e) Encourage omega-3-fatty acid intake:  
Omega-3-fatty acid consumption results in reduction TG levels and it also 
have cardio protective effects. Thus AHA recommends at least 1 fatty fish meal 
or other source of omega 3-fatty acids per week. 
 
(f) Increase dietary fiber intake:  
Soluble fiber intake will reduce the LDL cholesterol levels. Fruits, 
vegetables, cereals, oats, whole grains, and legumes are good sources of soluble 
fiber. 
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(g) Encourage antioxidant food sources:  
There is valuable evidence regarding various antioxidants which plays a 
significant role in decreasing the incidence of coronary heart disease. Various 
antioxidants like carotenoids (Lycopene) and vitamins C and E have been 
attributed with lower cardiovascular risk. So, the recommended intake of foods 
rich in antioxidants such as tomatoes, citrus fruits, papaya, whole grains, melons, 
berries and dark orange/yellow or leafy green vegetables are helpful in reducing 
various cardiovascular events rather than other food supplements. 
 
(h) Reduce serum homocysteine levels:  
Coronary heart disease is also associated with high blood levels of 
homocysteine. Intake of folate, vitamins B6, B12 and total fat restriction keep a 
check on homocysteine levels.  
 
(i) Avoid Plant sterols:  
Plant-sterol containing foods are associated with reducing low density 
lipoprotein cholesterol. But this is a double edged sword as it reduces the 
absorption of fat-soluble vitamins. Therefore, American Heart Association 
recommends these foods, such as ―cholesterol-lowering‖ margarine-type spreads 
and salad dressings, mainly for adult and usage for adolescents should not be 
generalized and should be used for those who are hyperlipidemic and monitored 
closely for growth
22
. 
2. INCREASED PHYSICAL ACTIVITY 
     Exercise programs like daily 30 minutes moderate intensity of physical activity which 
burns about 210 kcal/day approximately consuming 4-7 kcal/min have a valuable support 
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in reducing the cardiovascular risk. This is recommended by American Heart 
Association which is a reasonable and feasible approach to fitness therapy.  
3. ELIMINATION OF ASSOCIATED RISK FACTORS 
     Increased alcohol consumption among our individuals is most common in 
increasing the cardiovascular risk. So, individuals who wish to drink should restrict their 
limit to 2 or fewer standard drinks per day. Also, individuals who present with increased 
triglyceride levels are strictly recommended to eliminate or decrease alcohol intake. 
     Another most common risk factor for cardiovascular risk is smoking. For 
smoking individuals, they are advised to quit smoking and the better way for the younger 
individuals are encouraged not to smoke. For individuals who are unable to quit 
smoking, various smoking cessation therapies are available which includes nicotine 
replacement therapy and drug therapy
23
. 
4. MEDICAL MANAGEMENT OF HYPERLIPIDEMIAS: 
1. HMG Co-A inhibitor  
Atorvastatin  
Lovastatin                     
Fluvastatin     
Rosuvastatin 
Simvastatin      
Pravastatin 
2. Lipoprotein lipase activator 
Bezafibrate  
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Clofibrate    
Gemfibrozil        
Fenofibrate 
3. Resins sequestrating bile acid  
Colestipol 
Cholestyramine 
Colesevelam 
4. Cholesterol absorption inhibitors 
Ezetimibe 
5. Triglyceride synthesis inhibitor 
Nicotinic acid  
6. Miscellaneous 
Probucol
24 
Anti-oxidants – eg.  Lycopene 
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Site of action of Statins, Fibrates, Ezetimibe and Resins used in 
Hypercholesterolemia   
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1. HMG-CO-A REDUCTASE INHIBITORS 
ATORVASTATIN 
HISTORY: 
   In 1976, statins were first derived from a mould, Penicillium citrinum, and 
identified as inhibitors of cholesterol synthesis. Their mechanism of action is by 
inhibiting HMG-CoA reductase.
 
Compactin, later renamed as mevastatin was the first statin studied in humans. 
Lovastatin (formerly known as mevinolin) was the first developed statin and approved 
for use in humans, which was isolated from Aspergillus terreus. Six other statins are also 
available at present.  The chemically modified derivatives of lovastatin are Simvastatin 
and Pravastatin. The structurally distinct synthetic compounds are atorvastatin, 
rosuvastatin, fluvastatin, and pitavastatin.
 
CHEMISTRY 
 The structure of Atorvastatin is (C33H34FN2O5)2 Ca3H2O.  
 Atorvastatin calcium is a white crystalline powder. 
  In acidic pH, it is insoluble.  
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MECHANISM OF ACTION 
The major effects of statins are obtained by reducing LDL-C level through a 
mevalonic acid–like moiety which irreversibly inhibits the enzyme, HMG-CoA 
reductase. By inhibiting the conversion of pathway from HMG-CoA to mevalonate, 
which is the rate limiting step in the cholesterol synthesis, statins exert their inhibitory 
action at an early step. 
In the hepatocytes, the decreased cholesterol synthesis results in transcription of 
genes for the synthesis of LDL receptors. The membrane bound protein called SREBPs 
are undergoes proteolysis and translocated to the nucleus. The transcription factor then 
binds with the sterol-response element of the LDL receptor gene results in increased 
transcription and synthesis of LDL receptors. Thus increased number of LDL receptors 
on the surface of hepatocytes results in increased removal of LDL-C from the blood by 
means of receptor mediated endocytosis, thereby lowering the blood LDL-C levels. The 
LDL receptors degradation is reduced. Statins also can reduce the LDL-C levels by 
enhancing the removal of precursors of LDL like VLDL and IDL. It also decreases the 
production of hepatic VLDL. 
PHARMACOLOGICAL ACTIONS 
1. Triglyceride levels 
Statins are effective in reducing the triglyceride levels. The decrease in 
triglyceride levels achieved is similar to the level decreased in LDL cholesterol levels. 
The higher dose of most potent statins taken by hypertriglyceridemic patients observed a 
35-45% decrease in LDL-C and an equal amount of reduction in fasting triglyceride 
levels is also noted.  
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2.  HDL-C Levels 
Statins shows a modest rise in HDL cholesterol levels. About 5-15% of increase 
is noted. 
3. Effects of Statins on LDL-C Levels 
Statins lower LDL-C upto 60%. The decrease in LDL cholesterol level is 
augmented with the addition of nicotinic acid in combination with statins. 
4. Potential Cardio protective effects other than LDL-C lowering. 
i. Action on endothelium 
Vasoconstrictors and vasodilators play a dynamic role in the vascular 
endothelium in causing coronary heart disease. Statins plays an important role in 
endothelium by enhancing the production of a potent vasodilator Nitric oxide. 
Thus the vasodilating action improves the endothelial function and results in 
protection against cardiovascular risk.  
ii. Plaque Stability 
Statins inhibit infiltration of certain monocytes into the artery wall. They 
also inhibit secretion of matrix metalloproteinase (MMP) from the macrophages 
which normally degrades the extracellular matrix results in weakening of the 
fibrous cap. This will leads to the disruption of the atherosclerotic plaques. Thus 
by inhibiting MMP, prevent weakening of plaques that have formed. Other action 
in preventing atherosclerosis is by inhibiting smooth muscle cell proliferation and 
also by enhancing apoptosis. 
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iii. Anti- Inflammatory action 
In coronary heart disease, the normal C- reactive protein levels will be 
elevated. Thus increase in C- reactive protein levels also said to be the risk factor 
for coronary heart disease. Recently, evidence has been shown proving this 
statement. Statins decrease the C- reactive protein levels. This is one of the anti-
inflammatory actions noted in statins. 
iv.  Lipoprotein Oxidation 
Oxidation of lipoproteins is the foremost mediating factor for the 
formation of atherosclerosis. The oxidized LDL cholesterol is taken up by the 
macrophages which results in the formation of foam cells. The oxidized 
lipoproteins also induce cytotoxicity inside the atherosclerotic lesions. Thus, 
statins reduce this oxidative reaction of lipoproteins and thereby decreasing the 
uptake of oxidized lipoproteins within the macrophages. 
v. Coagulation 
Statins mainly reduce the aggregation of platelets and reduce the adhesion 
molecules.  Increased fibrinogen levels are associated with a greater in the 
incidence of cardiovascular risk. 
 Atorvastatin has an additional anti-oxidant property. 
PHARMACOKINETICS 
     Atorvastatin is rapidly absorbed from the stomach if administered orally. Atorvastatin 
has a longer plasma half life t 
½
 = 18 -24 hrs. It is > 98% bound to plasma proteins. It is 
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metabolized in the liver and the metabolites are important in exerting the HMG-Co-A 
inhibiting activity. It is eliminated primarily in bile.  
 USES 
1. They are the first line drug for treatment of Hyperlipidemia with elevated LDL-C 
and total cholesterol levels. 
2.  It is also effective in secondary hypercholesterolemia eg: Diabetes and Nephrotic 
syndrome. 
3. It also used in primary prevention of arterial disease in patients with risk factors for 
atherosclerosis. 
4. It is used as a prophylaxis in the prevention of myocardial infarction and stroke. 
ADVERSE EFFECTS 
   All statins are generally tolerated. 
Notable side effects are: 
1. Mild gastrointestinal complaints and headache. 
2. Rise in serum transaminase level occasionally. 
3. Muscle aches are the commonest side effect. Increase in CPK levels occur 
infrequently. 
4. Myopathy is more common when other drugs are used concurrently like nicotinic 
acid / gemfibrozil or CYP3A4 inhibitor ketoconazole/erythromycin/cyclosporine. 
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2. LIPOPROTEIN LIPASE ACTIVATOR  
Gemfibrozil, Benzafibrate and Fenofibrate cause reduction in VLDL levels. 
MECHANISM OF ACTION 
       Fibrates are derivatives of isobutyric acid activating the enzyme lipoprotein lipase, 
most important in catabolism of VLDL. This results in decreasing levels of VLDL which 
ultimately results in lowering of TG level. The nuclear transcription gene regulating 
receptor, PPARα activation cause enhancement of lipoprotein lipase synthesis and fatty 
acid oxidation. PPARα also mediate the enhancement of LDL receptor expression in the 
hepatocytes. 
 The triglyceride levels are lowered about 20-50% and decrease in LDL 
cholesterol levels about 10-15%. 
THERAPEUTIC USES 
 It is the first line drug for patients with increased triglyceride levels.  
 Acute pancreatitis is prevented in patients with severe hypertriglyceridemia 
and chylomicronaemia. 
ADVERSE EFFECTS 
Side effects are rare which includes gastrointestinal symptoms, rashes, impotence, 
myopathy, blurred vision, hypokalemia and increased blood levels of aminotransferases 
or alkaline phosphatase. 
3. RESINS SEQUESTRATING BILE ACID  
Cholestyramine, Colestipol and Colesevelam are the bile acid sequestrants useful 
only for patients with isolated increase in LDL. 
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MECHANISM OF ACTION 
     These drugs are the basic ion exchange resins available in the chloride form. After 
oral administration these drugs are neither digested nor absorbed in the stomach. It binds 
with the bile acids in the intestine and interrupts the bile acid entero-hepatic circulation. 
Faecal excretion of bile salts and cholesterol is increased. This indirectly leads to 
enhanced hepatic metabolism of cholesterol to bile acids. 
ADVERSE EFFECTS 
   Flatulence and other gastrointestinal symptoms occur. 
4. CHOLESTEROL ABSORPTION INHIBITORS25 
      Ezetimibe is a novel drug which acts by inhibiting cholesterol absorption from the 
intestine. It is rapidly absorbed from the gut and undergoes conjugation with the 
glucuronide in the intestine and excreted. The plasma half life was about 22 hours. 
MECHANISM OF ACTION 
       Its main mechanism is interfering with a specific cholesterol transport protein called 
NPC1L1 inside the intestinal mucosa. This results in decreased absorption of both 
dietary and biliary cholesterol. The enhanced cholesterol synthesis can be blocked by 
statins, and the two drugs have synergistic LDL-CH lowering effect. 
ADVERSE EFFECT 
                    Reversible hepatic dysfunction and rarely myositis have been noted. 
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5. INHIBIT TRIGLYCERIDE SYNTHESIS AND LIPOLYSIS 
     Nicotinic acid is a B group vitamin, in higher doses decreases Triglycerides and 
VLDL-C rapidly followed by modest fall in LDL-C and Total Cholesterol. It is primarily 
excreted in the urine. 
MECHANISM OF ACTION 
           The synthesis of triglyceride is inhibited by niacin which results in decreased 
release of VLDL in the liver. IDL and LDL are also reduced indirectly. It increases the 
activity of lipoprotein lipase that hydrolyse triglycerides. 
USES 
     Combined with resins or statins, niacin reduces LDL cholesterol levels in 
heterozygous familial hypercholesterolemia patients. 
ADVERSE EFFECTS 
        As nicotinic acid is a cutaneous vasodilator, marked flushing, itching occurs. This is 
associated with release of PGD2 in the skin. Aspirin taken before niacin substantially 
attenuates flushing by inhibiting PG synthesis. Laropiprant is a specific anti-flushing 
drug with no hypolipidemic action has been combined with nicotinic acid to minimize 
flushing. 
   Dyspepsia, vomiting, diarrhea can occur. Dryness, hyper pigmentation of skin, liver 
dysfunction and jaundice, hyperglycemia, hyperuricaemia, atrial arrhythmia also occurs. 
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PROBUCOL 
   It is one of the anti-hyperlipidemic agent acts by inhibiting the cholesterol synthesis 
and cholesterol absorption. It also increases the rate of LDL degradation. It may also 
lower the HDL levels. 
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OXIDATIVE STRESS 
It is defined as an ‗imbalance between free radical production and scavenging 
system predisposing to various pathological diseases‘ 
 ‗A free radical (Reactive Oxygen Species) is defined as an atom with one or more 
unpaired electrons, capable of independent existence‘ 
 
The reactive oxygen species (ROS) includes 
 Superoxide anion radical (O2- ) 
 Hydrogen peroxide (H2O2-) 
 Hydroxyl radical (OH- ) 
 Nitro radical (ONOO-) 
Oxidative stress induced by reactive oxygen species (ROS) plays an important role 
in the etiology of several chronic diseases including coronary heart disease. Oxidation of 
the circulating LDL which carries cholesterol into the blood stream plays a key role in 
the pathogenesis of atherosclerosis.  
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ANTI-OXIDANTS
27 
  „An anti-oxidant is a molecule stable enough to donate an electron to a free 
radical and neutralise it, thus reducing its capacity for tissue damage‘ 
 
CLASSIFICATION 1 
 ENDOGENOUS — Ubiquinone, glutathione, uric acid 
 EXOGENOUS — Vitamin E, Vitamin C, Carotenoids (Lycopene) 
 
CLASSIFICATION 2 
 PRIMARY — Vitamin E, Vitamin C, carotenoids (Lycopene), ubiquinone, lipoic 
acid 
 SECONDARY — N-Acetylcysteine, copper, glutathione reductase 
 
USES:   
 Used in Hyperlipidemia, diabetes mellitus, hypertension, stroke, atherosclerosis, 
senility, auto-immune disorders, osteoarthritis, H. pylori infection, etc., 
Nutrients rich in antioxidants which have their ability to inhibit the oxidative 
process are believed to slow the progression of atherosclerosis. Thus antioxidants are the 
agents inactivating the ROS and therefore they significantly prevent the oxidative 
damage to the tissues. 
Lycopene is one of the natural antioxidant which restores the endogenous 
antioxidant enzymes like superoxide dismutase (SOD), glutathione peroxidase (GSH-
Px), reduced glutathione (GSH), and glutathione reductase (GR).  
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In the previous study, Bose et al showed a significant increase in the level of 
antioxidant enzymes which demonstrated the antioxidant properties of tomato lycopene 
after 60 days of dietary supplementation of tomato in the coronary heart disease patients 
with respect to the control group and showed that it had a considerable therapeutic 
potential as an antioxidant
28
. 
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LYCOPENE 
Lycopene is a carotenoid phytonutrient without provitamin-A activity.  
Lycopene is derived from the word neo-Latin lycopersicum, the tomato species. 
 Other name: rhodopurpurin 
 Scientific name: non-provitamin A carotenoid. 
It is present in many fruits and vegetables. It is a red, fat-soluble pigment found 
in certain plants and micro-organisms.  
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SOURCE 
Major sources of lycopene in our diet includes 
 Gac fruit (Momordica cochinchinensis),  
                   
 Tomatoes (Lycopersicon esculentum) 
 Tomato products including tomato juice, ketchup, and pizza sauce.  
                                           
 It is also found in watermelon, papaya, pink grapefruit, and pink guava29.  
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STRUCTURE OF LYCOPENE 
                                
It is an isomer of β-carotene with an acyclic ring which contains 11 conjugated 
double bonds and 2 non-conjugated double bonds arranged in a linear array. Because of 
the presence of high number of conjugated dienes in their structure it is considered as the 
one of the most potent antioxidant. 
Lycopene is mainly given importance these days due to its antioxidant property 
as many diseases have been found to be associated with decreased level of these 
antioxidants nowadays.  It has a single oxygen quenching activity two times higher than 
β-carotene, 10 times higher than α-tocopherol signifying that lycopene has antioxidant 
property higher than these compounds
29
. 
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BIOAVAILABILITY AND PHARMACOKINETICS 
Lycopene is naturally present as all-trans form in its major sources like tomatoes. 
This form is poorly absorbed from the gut mucosa. Processing of tomatoes causes 
lycopene isomerization from its all-trans form to cis form which results in increasing 
bioavailability signifying that the processed forms are more useful for us
30
.  
High fat diet increases the absorption of lycopene as it is a fat soluble compound. 
The concentration of lycopene in body tissues is higher compared to other carotenoids.                                                               
 In the small intestine it is incorporated with lipid micelles. These lycopene 
containing lipid micelles are solubilized in their hydrophobic form which helps to enter 
into the intestinal mucosal cells by means of passive diffusion. In the blood plasma, 
lycopene is taken up by the very low and low-density lipoprotein fractions.  
Lycopene is widely taken up by various fatty tissues and to the organs such as the 
liver, adrenal glands, skin and testes. Lycopene levels are decreased with increasing age. 
But in individuals among smokers and alcoholics, the serum value of lycopene does not 
show any decreased levels
31
. 
The maximum concentration of lycopene after ingestion ranges from 15.6 to 32.6 
h.The mean half-life of lycopene is between 28.1 and 61.6 h.  
MECHANISM OF ACTION 
The biological activities of carotenoids such as β- carotene are related in general 
to their ability to form vitamin A within the body
32
. 
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Although lycopene being an isomer of carotene, it cannot form vitamin A 
because of the lack of β-ionone ring in its structure. Thus the biological effects of 
lycopene in humans have therefore been attributed to mechanisms other than vitamin A.  
The presence of eleven conjugated double bonds in its structure has been 
attributed to its anti-oxidant property. 
 
 Two major hypotheses have been proposed to explain the anti-
carcinogenic and anti-atherogenic activities of lycopene:  
1. Non-oxidative effects 
2. Oxidative effects 
 
1. The non-oxidative mechanism explains the anti-carcinogenic effect of lycopene. It 
primarily regulates the gap-junction communication between the cells demonstrated 
in the fibroblast cells of mouse embryo
33
. 
2. Oxidative mechanism – it protects LDL-C from oxidation and suppress cholesterol 
synthesis. 
3. Hypocholesterolemic agent- inhibits 3-hydroxy-3-methylglutaryl–coenzyme A 
reductase enzyme. 
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Lycopene 
 
Non- oxidative hypothesis Oxidative hypothesis 
Increase endogenous 
antioxidant potential 
Neutralize Reactive 
oxygen species 
Decrease oxidative 
damage to lipids, 
proteins and DNA 
1. Gap junction 
communication 
2. Cell cycle regulation 
3. Modulation of gene 
expression 
4. Improvement of 
immune response 
Decrease oxidative stress 
Reduced risk of Chronic Diseases 
(Cancer, Hypertension, Cardiovascular 
disease, Neurodegenerative disease, 
Osteoporosis. 
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4. It protects various cellular bio molecules like lipids and lipoproteins which prevents 
the formation of atherogenesis. It also protects proteins and DNA molecules 
contributing to its anti-carcinogenic effect. 
5. It suppresses phosphorylation of p53 and Rb anti-oncogenes which are common 
regulatory proteins affected by the carcinogens. It also stops cell cycle at the G0–G1 
phase
34
. 
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6. In the rat liver the carcinogen induced pre-neoplastic lesions are prevented by 
modulating the liver metabolizing enzyme, cytochrome P4502E1, this modulation 
helps in the protection against the carcinogen
35, 36
. 
7. In various cancers, insulin-like growth factors act as a potent mitogen causing 
proliferation of cells. Lycopene shows reduced cellular proliferation induced by 
insulin-like growth factor
37
. 
8. Suppression of mammary tumour growth by regulating intrathymic T-cell 
differentiation (immunomodulation)
38
 
 
EFFECT OF LYCOPENE ON LIPID METABOLISM 
 Recently lycopene is also getting importance because of its effect on cholesterol 
metabolism and its long term effect on atherosclerosis. Following are the effects of 
lycopene on cholesterol metabolism
39, 40
: 
 
1. The biosynthesis of cholesterol and isoprenoids is catalyzed by a specific rate 
limiting enzyme HMG-CoA reductase enzyme promoting deacylation of 
HMG-CoA to mevalonate.  
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2. Reduction of intracellular cholesterol by decreasing cholesterol synthesis 
through an inhibition of HMG-CoA reductase activity and expression, and 
modulation of LDL receptor and ACAT activity. The mechanism of HMG-
CoA reductase enzyme is regulated by negative feedback mechanism by both 
the sterols and non-sterol products of the mevalonate pathway
41
. 
3. In J-774 A.1 macrophage cell line, lycopene suppress mainly synthesis of 
cholesterol from [3 H]-acetate, rather than from [14 C] mevalonate.  
4. Lycopene reduces the serum cholesterol concentration by decreasing the 
cholesterol biosynthesis and also by enhancing the uptake through activation 
of the LDL receptors. Increased uptake of LDL by the macrophages enriched 
65 
 
with lycopene compared to the uptake of LDL by the cholesterol enriched 
macrophages has been noted
42
. 
5. Cholesterol regulates HMG-CoA reductase gene transcription. Statins 
competitively inhibits this enzyme whereas; lycopene inhibits this enzyme at 
the post transcriptional level. 
Furhman et al, showed the effect of lycopene in six healthy male subjects 
consuming 60 mg/day of lycopene for three months duration. At the end of treatment 
period, a significant 14% reduction in their plasma LDL-C level was observed. 
       In postmenopausal women, supplementation with tomato extract capsules (4 mg 
lycopene) daily for 6 months duration also results in decreased total cholesterol and LDL 
cholesterol levels.  
 
EFFECT OF LYCOPENE IN ATHEROGENESIS 
1. In atherogenesis, the various inflammatory mediators like tumor necrosis factor 
(TNF-α) and interleukin (IL)-1β, and IL-8 enhance the binding of low-density 
lipoprotein to endothelial surface and enhance the up-regulation and expression 
of leukocyte adhesion molecules on the endothelium
43
.
  
These inflammatory 
mediators play a major role in atherogenesis. Low density lipoproteins are the 
main carrier of cholesterol into the blood stream. Thus the oxidation of the low 
density lipoproteins forming oxidized LDL (LDLox) is thought to play an 
important role in the atherogenesis. Atherosclerosis is the underlying disorder 
causing cardiovascular events like heart attack and stroke. 
2. Thus lycopene exerts its anti-atherogenic effect at the level of these inflammatory 
mediators preventing the formation of atherogenesis. It also has an additional 
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effect in inhibiting TNF-α-induced NF-κB activation, monocyte-endothelial 
interaction and ICAM-1 expression in human umbilical endothelial cells.  
3. Lycopene also suppresses the transcription reactions TNF-α-induced IκB 
phosphorylation, NF-κB expression, and NF-κB p65 translocation from the 
cytosol to nucleus
44
. 
4. Thus, in the prevention of atherosclerosis, lycopene shows significant reduction 
in the levels of oxidized LDL (LDLox), thereby reducing the level of cholesterol 
in the blood stream
45
. 
 In a study by Visioli et al, 12 females were allowed to consume tomato products like 
raw tomatoes, sauce and paste for three weeks duration. In these individuals it shows 
increased lycopene concentration in their blood and also reduced oxidizability of 
LDL cholesterol levels. This concluded that lycopene present in the tomato products 
decreases lipid peroxidation, thereby protects from atherosclerosis
46
. 
 
EFFECT OF LYCOPENE ON PREVENTING CANCER 
1. Increased intake of lycopene shown to reduce the incidence of various cancers 
like cancers of the colon, pancreas, rectum, esophagus, oral cavity, cervix and 
breast
 47
. 
2. In oxidative mechanism, it shows to protect the cellular biomolecules like 
proteins and DNA from oxidative damage. Thus the oxidative damage to DNA 
was reduced and shows 20% significant decline in incidence of prostate cancer
48
. 
3. Lycopene decreases cellular proliferation in various cell lines. By down-
regulating the PI-3K/Akt/mTOR signaling pathway and decreased proliferation of 
HT-29 cells in the human colon results in suppression of colon cancer
49
. 
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4. In human cultured skin fibroblast, it binds with the platelet –derived growth 
factor-BB. This results in inhibition of platelet-derived growth factor-BB–
induced signaling and cell migration
50
. 
5. In prostate cancer cell lines, lycopene enhance the induction of apoptosis and it 
also inhibits the cell growth in androgen-sensitive (LNCaP) and androgen-
independent (PC3 and VeCaP) cells
51
. 
6. In old age men, daily intake lycopene containing 15 mg/day shown to inhibits the 
progression of benign prostate hyperplasia
52
. 
7. A gene called Connexin 43 is present in both human and animal cells. In many 
human tumors, there is a defect in the intercellular gap junction which causes 
increased proliferation of cancer cells. Lycopene up regulates the expression of 
this gene resulting in restoration of intercellular gap junction communication and 
associated with decreased proliferation of cancer cells
53
. 
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Anticancer mechanism of lycopene
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EFFECT OF LYCOPENE ON OSTEOPOROSIS 
1. Oxidative stress and antioxidants play a major role in the pathogenesis of 
osteoporosis
54
. 
2. Endogenous antioxidants decrease the effects of stress induced by reactive oxygen 
species in these cells, thus lycopene decrease the damaging effects of oxidative 
stress. 
3.  Lycopene has bone remodelling effect by increasing the bone mineral density 
primarily by increasing the alkaline phosphatase of osteoblasts. It also has anti-
resorptive property by inhibiting the osteoclast formation and maturation
55
. 
4. Lycopene also decreases the level of resorptive elements like N-telopeptides of 
type I collagen (NTx) 
56
. 
 
MALE INFERTILITY 
Infertility in males is a common reproductive disorder occurs due to the oxidative 
damage of the sperm. Lycopene being an antioxidant property it shows benefits in sperm 
morphology, sperm motility, sperm motility index, and functional sperm concentration. 
The effective response is observed by continuous intake of lycopene for 12 months 
duration
57
. 
 
EFFECT OF LYCOPENE ON PROTECTION OF HEPATIC DAMAGE 
 Hepatic damage occurs by necrosis of hepatocytes, increase in tissue lipid 
peroxidation, and depletion of tissue endogenous antioxidant enzymes like GSH levels. 
The various serum biochemical markers like serum glutamic oxaloacetic transaminase, 
serum glutamic pyruvic transaminase, triglycerides, cholesterol, bilirubin, and alkaline 
phosphatase are elevated when hepatic damage is present
58
.  
70 
 
In an animal model, the protective effect of lycopene was demonstrated. A rat 
with galactosamine/lipopolysaccharide (D-GalN/LPS)-induced hepatitis was injected 
lycopene intraperitonealy a dose of 10 mg/kg. The serum concentration of biochemical 
markers are shown to be reduced in this animal model.  
The decrease in biochemical markers like triglyceride, cholesterol and free fatty 
acids showed a protective effect in hepatic damage
59
.  
In another study it was demonstrated that lycopene significantly restored the 
endogenous antioxidant liver enzymes, such as glutathione peroxidase, glutathione-s-
transferase, which is protective in many disease caused by oxidative stress
60
. 
 
EFFECT ON EYE DISORDERS 
Cataract is the most common multifactorial disorder. It usually occurs in elderly 
people. In diabetic individuals, increased osmotic stress and decreased antioxidant 
defense mechanisms are contributes to the changes observed in the eye predisposing to 
the formation of cataract. In various epidemiological studies, the nutritional antioxidants 
decrease the progression of cataract formation and age-related macular degeneration
61
. 
 In an in vitro study, lycopene protects the human retinal pigment epithelium cell 
line ARPE-19 against the H2O2-induced oxidative stress
62
.
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OTHER DISEASES 
1. Lycopene is a fat soluble compound which crosses the blood brain barrier. 
Human brain is a common organ for affected by oxidative damage due to it‘s 
increased uptake of oxygen and utilization. Brain also possesses low antioxidant 
effects. In normal individuals low concentration of lycopene is present in the 
brain which has a protective effect. 
2. Lycopene is decreased in elderly individuals and it shows that there is significant 
reduction in the lycopene levels in most common diseases like Parkinson‘s 
disease and vascular dementia
63
. 
3. Lycopene was also suggested as providing protection against amyotrophic lateral 
sclerosis (ALS) disorder in humans
64
. 
4. It also shows a protective role in neurodegenerative diseases like 
Alzheimer‘sdisease65.  
5. Future research will also explore the importance of lycopene in other human 
diseases including rheumatoid arthritis, diabetes, ocular and skin disorders, 
periodontal diseases and inflammatory disorders
66
. 
 
RECOMMENDED DAILY ALLOWANCE  
 In healthy individuals, daily intake of 5-7 mg/day of lycopene helps in 
combating oxidative stress and prevention of chronic illness. 
 15-20 mg/day of Lycopene shows significant effects on LDL oxidation, 
blood pressure, platelet activation and aggregation and DNA oxidative 
damages. 
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DRUG FORMULATIONS 
   It is available as 
 Soft gel capsules 
 
 Syrup  
 
    
ADVERSE EFFECTS 
Anorexia,  
Diarrhoea,  
Flatulence,  
Nausea,  
Vomiting,  
Skin discolouration,  
Abdominal pain. 
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DRUG INTERACTIONS 
1. May increase the risk of bleeding with aspirin, anticoagulants, heparin, anti-
platelet drugs, NSAIDs. 
PRECAUTIONS 
1. Persons who are allergic or sensitive to Lycopene. 
2. Pregnancy and breast feeding. 
 
Lycopene by acting as an antioxidant can prevent the progression of many diseases 
at an early stage and improve the quality of life. 
Lycopene with antioxidant effect helps in lowering blood lipid levels and may be 
beneficial in patients with hyperlipidemia. Since few studies are available on lipid 
lowering effect of lycopene, this study has been undertaken to assess the hypolipidemic 
effect in comparison with Atorvastatin. 
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AIM & OBJECTIVES 
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AIM 
 To evaluate the efficacy and tolerability of Lycopene as add on therapy to 
Atorvastatin in reducing the lipid levels in patients with hyperlipidemia.  
 
OBJECTIVES 
Primary objective: 
 Decrease in Total cholesterol and LDL cholesterol levels.  
Secondary objective: 
 Increase in HDL, decrease in VLDL, TGs.  
 Observe the adverse effects.  
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METHODOLOGY 
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METHODOLOGY 
This prospective study was done to assess the therapeutic effect of Lycopene in 
combination with Atorvastatin in decreasing the lipid profile. 
STUDY DESIGN 
This study was an open label, randomized, comparative, prospective study. 
STUDY CENTRE 
Department of Internal Medicine, Rajiv Gandhi Government General hospital, 
Madras Medical College, Chennai. 
STUDY PERIOD 
  The study was carried out from August 2013 to April 2014 with 8 weeks as 
treatment period every patient and follow-up every fortnightly till the end of the study. 
STUDY POPULATION 
Patients presenting with Hyperlipidemia attending Medicine OPD, 
RGGGH/MMC, Chennai. 
SAMPLE SIZE 
 Totally 100 patients 
 50 patients in each group (control and test groups)  
STUDY PROCEDURE: 
     The study was started after obtaining approval from the Institutional Ethics 
Committee. The patients were explained about the details of the study and an 
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information sheet and informed consent forms written in the regional language was 
provided to each patient and the patients willing to participate in this study signed the 
required forms. 
INCLUSION CRITERIA: 
1. Both genders. 
2. Age- 25 – 60 yrs. 
3. Subjects with total cholesterol level between 200-250 mg/dl. 
4. Patients with Stage I Hypertension and Type II Diabetes with glycaemic control. 
4. Patients willing to give written informed consent. 
EXCLUSION CRITERIA: 
1. Pregnant and lactating women. 
2. Subjects with evidence of clinically significant gastrointestinal, renal, respiratory,   
    endocrine, hematological, neurological, psychiatric or cardiovascular dysfunctions. 
3. Triglycerides > 250 mg/dl. 
4. Total cholesterol: HDL ratio > 4.5. 
5. H/o allergy or intolerance to lycopene. 
6. Patients unwilling or unable to comply with the study procedures. 
7. Those with history of alcohol or drug abuse. 
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SCREENING 
   The patients were screened with detailed clinical history, physical   
examination and  baseline investigations.  
          RECRUITMENT 
     Those who fulfilled the inclusion criteria were recruited for the study. 
 RANDOMIZATION: 
     The enrolled patients were randomized to the control or test group by simple 
randomization. 
 TREATMENT PLAN 
 CONTROL GROUP 
                       T. Atorvastatin 10mg/day for 8 weeks. 
              TEST GROUP 
                     T. Atorvastatin 10mg/day and Capsule Lycopene 15mg/day for 8 weeks. 
             The study medication was issued for 2 weeks. After assessing the compliance at 
the end of 2 weeks, study   medication was issued for the subsequent 2 weeks. The same 
procedure was followed till the completion of study.  
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INVESTIGATION: 
BASELINE INVESTIGATION 
o Complete blood count (Hemoglobin, Total count, Differential count, ESR 
and Platelets) 
o Fasting Blood sugar, Blood urea, Serum Creatinine. 
o SGOT, SGPT  
o Routine Urine Analysis 
     All the baseline investigations were done at the start of the study and at the end of the 
8 weeks. 
 Fasting Lipid Profile:  Serum (Total Cholesterol, LDL, VLDL, HDL & TGL) was done 
at baseline, 4
th
 week and at 8
th
 week of the study. 
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STUDY FLOW CHART 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ENROLLMENT 
 
RANDOMIZATION 
STUDY GROUP 
50 patients 
CONTROL GROUP 
50 patients 
T.ATORVASTATIN 10mg/day 
 
T.ATORVASTATIN 10mg/day 
and C.LYCOPENE 15 mg/day 
 
 
 
 
 
TREATMENT PERIOD – 8 WEEKS 
STATISTICAL ANALYSIS   
SCREENING 
 
 
Complete medical history, 
clinical examination, 
biochemical investigations.  
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STUDY VISITS 
Screening and Baseline 
1.  Demographic details obtained 
2. Complete medical history recorded 
3. Clinical examination performed 
4. Enrollment done 
5. Written informed consent obtained 
6. Vitals recorded 
7. Laboratory investigation 
 Complete blood count 
 Lipid profile 
 Blood urea, Sugar  
 Serum Creatinine 
 SGOT, SGPT  
 Urine analysis 
VISIT 1 (0 WEEKS) 
1. Randomization of patient 
2. Physical & Clinical examination 
3. Vitals recorded 
4. Drugs issued for Study group and control group patients 
5. Instruction to return the empty strips in the subsequent visit. 
 VISIT 2 (2 WEEKS) 
1. Received Empty drug strips 
2. Clinical examination was done 
3. Vitals recorded  
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4. Drugs issued for subsequent 2 weeks  
5. Instruction to return the empty strips in the subsequent visit. 
6. Patient advised to report any adverse event. 
VISIT 3 (4 WEEKS) 
1. Received Empty drug strips 
2. Clinical examination was done  
3. Vitals recorded 
4. Drugs issued for subsequent 2 weeks. 
5. Lipid profile 
6. Instruction to return the empty strips in the subsequent visit. 
7. Patient advised to report any adverse event  
VISIT 4 (6 WEEKS) 
1. Received Empty drug strips 
2. Clinical examination was done  
3. Vitals recorded 
4. Drugs issued for subsequent 2 weeks  
5. Instruction to return the empty strips in the subsequent visit. 
6. Patient advised to report any adverse event. 
VISIT 5 (8 WEEKS) 
1. Received Empty drug strips 
2. Clinical examination was done  
3. Vitals recorded 
4.   Laboratory investigation 
 Complete blood count 
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 Lipid profile 
 Blood urea, Sugar ,Serum Creatinine 
 SGOT, SGPT  
 Urine analysis 
INSTRUCTION TO PATIENTS 
    The patients were instructed clearly regarding the regular intake 
of the medicines. They were given proper advice to report for assessment and collection 
of drugs. They were counseled to report any adverse reactions occur. 
COMPLIANCE 
   Patient compliance was monitored by the empty strips returned at each visit. 
ADVERSE EVENTS:  
  Adverse event if any, reported by the patient or observed by the physician during 
the study was recorded. The onset of adverse event, causal relationship to the study drug 
and action taken was recorded.  
STATISTICAL ANALYSIS: 
The obtained data was analyzed statistically.  Distribution of age was analysed 
using ANOVA and Sex distribution was analyzed by Chi square test. 
 The biochemical investigations were performed at 0 week and 8
th
 week. The 
difference within the groups before and after treatment was analyzed using student‘s 
paired t-test whereas the difference between the Control and Study group were analyzed 
using students independent t-test.     
  p value < 0.05 is considered to be statistically significant. 
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RESULTS 
This study was conducted to evaluate the effect of lycopene in combination with 
atorvastatin in reducing lipid levels.  
 176 patients were screened  
 60 patients were excluded from the study based on exclusion criteria,  
 16 patients who were eligible for the study were not willing to participate.  
 100 patients were enrolled and completed the study. 
 There were no drop outs. 
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TABLE 1: AGE DISTRIBUTION 
 
 
AGE IN YEARS 
 
CONTROL 
 
TEST 
 
NO 
 
PERCENTAGE 
 
NO 
 
PERCENTAGE 
 
30-40 
 
12 
 
24% 
 
10 
 
20% 
 
41-50 
 
15 
 
30% 
 
13 
 
26% 
 
51-60 
 
17 
 
34% 
 
20 
 
40% 
 
>60 
 
6 
 
12% 
 
7 
 
14% 
 
TOTAL 
 
50 
 
100% 
 
50 
 
100% 
 
 Table 1 shows the age distribution of both the study groups. 
 Age group 51-60years had more number of patients followed by age 
group 41-50. 
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FIGURE 1: AGE DISTRIBUTION 
 
 
 
 Figure 1 depicts age distribution in both the study groups. 
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TABLE 2: MEAN AGE DISTRIBUTION 
 
 
GROUP 
 
No of patients 
 
MEAN AGE 
( in years ) 
 
SD 
 
Control 
 
50 
 
49.6 
 
12.65 
 
Test 
 
50 
 
49.2 
 
12.41 
 
       p value                                                           0.893 
 
 
 Table 2 shows the mean age of both the study groups. 
 The mean age was similar in both the groups. 
 There was no statistically significant difference between the groups. 
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 FIGURE 2: MEAN AGE DISTRIBUTION 
 
 
 
 Figure 2 is the graphical representation of Table 2. 
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TABLE 3: SEX DISTRIBUTION 
 
 
 
 
SEX 
DISTRIBUTION 
 
CONTROL 
 
 
STUDY 
 
NO. OF 
PATIENTS 
 
 
% 
 
NO. OF 
PATIENTS 
 
% 
MALE 35 70% 32 64% 
FEMALE 15 30% 18 36% 
TOTAL NO. OF 
PATIENTS 
50  50  
 
 Table 3 shows the sex distribution in both the groups. 
 Males were more in number compared to females in both groups. 
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FIGURE 3: SEX DISTRIBUTION 
           
 
 Figure 3 depicts Table 3. 
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TABLE 4: TOTAL CHOLESTEROL 
GROUPS 0 WEEKS 8 WEEKS p value 
 
MEAN 
 
SD 
 
MEAN 
SD 
CONTROL 216.68 15.94 189.12 10.87 <0.001 
TEST    220.28 16.78 181.16 11.34 <0.001 
p value 0.274 0.01  
 
 Table 4 shows the mean Cholesterol value of both study groups at baseline & end 
of 8 weeks. 
 On comparing with baseline, both groups showed a decrease in mean Total 
cholesterol. 
 Statistical analysis within the groups showed a significant decrease in the Total 
cholesterol at the end of 8weeks (p <0.001). 
 Statistical analysis between the groups showed a significant difference at the end 
of 8 weeks (p =0.01). 
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FIGURE 4: TOTAL CHOLESTEROL 
 
 Figure 4 is the graphical representation of Table 4. 
 
 
 
 
 
 
 
 
216.68 220.28
189.12
181.16
0
50
100
150
200
250
CONTROL TEST
M
E
A
N
 T
O
T
A
L
 C
H
O
L
E
S
T
E
R
O
L
m
g
/d
l 
 
0 WEEKS
8WEEKS
95 
 
TABLE 5: LDL CHOLESTEROL 
GROUPS 0 WEEKS 8 WEEKS p value 
 
MEAN 
 
SD 
 
   MEAN 
SD 
CONTROL 141.1 15.92 116.33 11.79 <0.001 
TEST    147.41 2.70 109.46 1.63 <0.001 
p value 0.08 0.004  
 
 Table 5 shows mean LDL cholesterol levels of both the groups at baseline & 
end of 8 weeks. 
 There was a significant reduction in the mean LDL cholesterol levels in the 
test group (109.46mg.dl) compared to the control group (116.33mg/dl) at the 
end of 8 weeks. 
 Statistical analysis within the group showed a significant decrease in both the 
study groups (p <0.001) 
 Statistical analysis between the groups at the end of 8 weeks showed a 
significant difference. 
 
 
 
96 
 
FIGURE 5: LDL CHOLESTEROL 
 
 Figure 5 depicts Table 5. 
 
 
 
 
 
 
 
 
141.1
147.41
116.33
109.46
0
20
40
60
80
100
120
140
160
CONTROL TEST
M
E
A
N
 L
D
L
-C
 m
g
/d
l
0 WEEKS
8 WEEKS
97 
 
TABLE 6: HDL CHOLESTEROL 
 
 Table 6 shows mean HDL cholesterol levels in both the groups at baseline & end 
of 8 weeks. 
 Statistical analysis within the groups showed a significant decrease in the HDL 
level at the end of 8 weeks (p <0.001). 
 Statistical analysis between the groups did not show a significant difference at the 
end of 8 weeks. 
 
 
 
 
 
GROUPS 0 WEEKS 8 WEEKS p value 
 
MEAN 
 
SD 
 
   MEAN 
SD 
CONTROL 39.2 1.76 41.4 1.64 <0.001 
TEST    38.45 2.11 41.40 2.13 <0.001 
p value 0.059 0.958  
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FIGURE 6: HDL CHOLESTEROL 
 
 Figure 6 is the diagrammatic representation of Table 6. 
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TABLE 7: VLDL CHOLESTEROL 
GROUPS 0 WEEKS 8 WEEKS p value 
 
MEAN 
 
SD 
 
   MEAN 
SD 
CONTROL 36.31 3.18 31.59 1.50 <0.001 
TEST    36.57 3.6 31.62 1.69 <0.001 
p value 0.704 0.921  
 
 Table 7 shows mean VLDL levels in both groups at Baseline and at the 
end of 8 weeks. 
 Statistical analysis within the groups showed a significant decrease in the 
VLDL level at the end of 8 weeks (p <0.001). 
 Statistical analysis between the groups did not show a significant 
difference at the end of 8 weeks. 
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FIGURE 7: VLDL CHOLESTEROL 
 
 Figure 7 depicts Table 7. 
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TABLE 8: TRIGLYCERIDE LEVELS 
 
 Table 8 shows mean Triglyceride level in both groups. 
 Statistical analysis within the groups showed a significant decrease in the 
Triglyceride level at the end of 8 weeks (p <0.001). 
 Statistical analysis between the groups did not show a significant difference at the 
end of 8 weeks. 
 
 
 
 
 
GROUPS 0 WEEKS 8 WEEKS p value 
 
MEAN 
 
SD 
 
   MEAN 
SD 
CONTROL 181.48 15.93 157.96 7.54 <0.001 
TEST    180.84 21.4 158.08 8.48 <0.001 
p value 0.866 0.941  
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FIGURE 8: TRIGLYCERIDE LEVEL 
 
 Figure 8 is the graphical representation of Table 8. 
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TABLE 9: HYPERTENSION AND DIABETES 
 
 Table 9 shows the associated conditions in patients of both the study groups. 
 Patients with Hypertension were more in both groups (Control group – 20, Test 
group – 24) followed by Non DM/HT (Control group-19, Test group-14). 
 
 
 
 
 
 
ASSOCIATED 
CONDITIONS 
CONTROL TEST TOTAL 
HYPERTENSION 20 24 44 
DIABETES 5 8 13 
HYPERTENSION 
AND DIABETES 
6 4 10 
NON HT/DM 19 14 33 
TOTAL 50 50 100 
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FIGURE 9: HYPERTENSION AND DIABETES 
 
 
 Figure 9 is the diagrammatic representation of associated conditions in 
patients of both the study groups. 
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TABLE 10: BIOCHEMICAL INVESTIGATION (CONTROL GROUP) 
 
Investigations                   Control group p value 
0 WEEKS 8 WEEKS 
Blood urea 24.88±3.37 24.46±3.24 0.528 
Blood sugar 103.10±19.5 100.7±8.93 0.634 
Serum Creatinine 0.65±0.13 0.67±0.14 0.545 
SGOT 28.26±4.66 27.62±4.54 0.561 
SGPT 30.32±4.97 30.16±4.90 0.90 
Total count 8188.8±1411.90 8159±1411.1 0.221 
Hemoglobin 11.48±1.00 11.73±1.02 0.303 
 
 Table 10 shows the Biochemical and Hematological parameters of the 
control group. 
 Statistical analysis within the groups and between the groups did not show 
any significant difference. 
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TABLE 11: BIOCHEMICAL INVESTIGATION (TEST GROUP) 
 
Investigations                   Test  group p value 
0 WEEKS 8 WEEKS 
Blood urea 24.86±3.45 25.11±3.48 0.696 
Blood sugar 107.6±19.68 104±12.27 0.754 
Serum Creatinine 0.68±0.14 0.67±0.14 0.744 
SGOT 27.92±4.33 28.46±4.37 0.588 
SGPT 30.30±4.72 30.04±4.71 0.770 
Total count 8309.5±1438.7 8274.7±1407.6 0.456 
Hemoglobin 11.68±1.09 11.75±1.24 0.220 
 
 Table 11 shows the Biochemical and Hematological parameters of the test group. 
 Statistical analysis within the groups and between the groups did not show any 
significant difference. 
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TABLE 12: ADVERSE DRUG REACTION 
 
 
ADVERSE DRUG 
REACTION 
 
CONTROL GROUP 
 
TEST GROUP 
 
Nausea 
 
3 (6%) 
 
5 (10%) 
 
Flatulence 
 
                 3 (6%) 
 
1 (2%) 
 
Diarrhoea 
 
3 (6%) 
 
2 (4%) 
 
Myalgia  
 
4 (8%) 
 
2 (4%) 
 
 Table 12 shows the adverse effect profile of both the study groups. 
 Gastrointestinal disturbances were reported more in both the study groups. 
 
 
 
 
 
 
108 
 
FIGURE 12: ADVERSE DRUG REACTION 
 
 Figure 12 is the graphical representation of adverse drug reaction. 
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TABLE 13: INCIDENCE OF ADRs 
 CONTROL GROUP TEST GROUP 
NUMBER OF 
ADRs 
13  10 
 
 Table 13 shows the incidence of ADRs presented by the patients in both the study 
groups. 
 In control group, 13 ADRs were reported and in Test group 10 ADRs were 
reported. 
FIGURE 13: INCIDENCE OF ADRs 
 
 Figure 13 shows the graphical representation of incidence of ADRs.  
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TABLE 14 : CAUSALITY ASSESSMENT OF INDIVIDUAL ADR IN CONTROL 
GROUP 
 
ADRs 
 
Certain 
 
Probable 
 
Possible 
 
 
Un-
likely 
 
Un- 
classified 
 
Un- 
classifiable 
 
Total 
 
Nausea 
 
- 
 
- 
 
3 
 
- 
 
- 
 
- 
 
3 
 
Flatulence 
 
- 
 
 
- 
 
3 
 
- 
 
- 
 
- 
 
3 
 
Diarrhoea 
 
- 
 
- 
 
3 
 
- 
 
- 
 
- 
 
3 
 
Myalgia 
 
- 
 
- 
 
4 
 
- 
 
- 
 
- 
 
4 
 
Total 
   
13 
    
13 
 
 Table 14 shows causality assessment of individual ADR in control group. 
 Causality assessment was done using WHO causality assessment scale 
 All adverse drug reactions were categorized as possible. 
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TABLE 15 : CAUSALITY ASSESSMENT OF INDIVIDUAL ADR IN TEST 
GROUP 
 
ADRs 
 
Certain 
 
Probable 
 
Possible 
 
 
Un-
likely 
 
Un- 
classified 
 
Un- 
classifiable 
 
Total 
 
Nausea 
 
- 
 
- 
 
5 
 
- 
 
- 
 
- 
 
5 
 
Flatulence 
 
- 
 
- 
 
1 
 
- 
 
- 
 
- 
 
1 
 
Diarrhoea 
 
- 
 
- 
 
2 
 
- 
 
- 
 
- 
 
2 
 
Myalgia 
 
- 
 
- 
 
2 
 
- 
 
- 
 
- 
 
2 
 
Total 
   
10 
    
10 
 
 Table 15 shows causality assessment of individual ADR in test group. 
 All ADRs were categorized as possible under WHO causality assessment scale. 
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TABLE 16: SEVERITY ASSESSMENT OF ADR 
 
 
SEVERITY 
 
CONTROL GROUP 
 
TEST GROUP 
 
MILD 
 
13  
 
10 
 
MODERATE 
 
- 
 
- 
 
SEVERE 
 
- 
 
- 
  
 Table 16 shows severity assessment of Adverse Drug Reactions. 
 Severity assessment was done using Modified Hartwig and Siegel scale. 
 All the Adverse Drug Reactions in control and study group were mild. 
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DISCUSSION 
Coronary heart disease is the most common cause of death worldwide. 
Abnormalities in lipoprotein metabolism are a major predisposing factor to 
atherosclerosis, increasing risk for CHD (Coronary heart disease).      
Hyperlipidemia characterized by increased levels of total cholesterol, LDL-C and 
triglycerides, is a major modifiable risk factor in primary and secondary prevention of 
Coronary Heart Disease. Oxidative stress induced by reactive oxygen species (ROS) is 
also considered to play an important role in the pathogenesis of hyperlipidemia.  
Statins are the most frequently used drugs in the treatment of hyperlipidemia. 
While statins are highly effective in controlling cholesterol levels, side effects including 
muscle pain, muscle weakness, and neuropathy are experienced by some patients.  
Lycopene is an antioxidant that suppresses cholesterol synthesis and prevents 
development of atherosclerosis.  
Therefore this study was taken up to assess the efficacy of Lycopene in 
combination with Atorvastatin in patients with Hyperlipidemia. 
The patients were screened by history, clinical examination and laboratory 
investigation. 
100 patients who fulfilled the eligibility criteria were enrolled and randomized 
into two groups of 50 patients in each group. One group received Atorvastatin and the 
other group received Atorvastatin plus Lycopene for 8 weeks duration. 
 
Hypocholesterolemic effect was assessed by fasting lipid profile and the results 
were analysed statistically. 
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The age and sex distribution did not show any statistically significant difference 
between the study groups. This shows that all the patients belonged to the same 
population. 
Atorvastatin reduces the LDL levels and this was observed in both the groups at 
the end of the study. But patients receiving Lycopene as add on therapy had a 
statistically significant reduction in LDL levels (p <0.01). The reduction is about 18% in 
control group compared to 26% in test group. 
At the end of 8 weeks, the total cholesterol levels showed a significant reduction 
in patients receiving Atorvastatin alone (12.7%) and also in patients with addition of 
Lycopene to Atorvastatin (17.7%) (p <0.001). On comparing both groups, there was a 
statistically significant reduction in Total cholesterol levels in patients with Lycopene as 
add on therapy (p < 0.001) in comparison to those receiving Atorvastatin alone  
This shows that addition of Lycopene contributes to the reduction of both   LDL 
and Total cholesterol levels. This was similar to the study conducted by Fuhrman et al, 
where reduction in plasma LDL-C level (14%) was observed. 
In Visioli et al study, three weeks supplementation of tomato products showed a 
significant lycopene concentration in their blood and also reduced oxidizability of LDL 
suggesting an important role for tomato products in the prevention of lipid peroxidation. 
The HDL, VLDL, TGs level did not show any significant difference between the 
groups. This shows that the addition of Lycopene did not affect these parameters. 
The hematological parameters like hemoglobin, total count, differential count, 
ESR and platelets did not show any significant difference in both study groups at the end 
of 8 weeks. 
There was no significant difference in biochemical parameters like blood sugar, 
urea, serum creatinine, SGOT, SGPT in both the groups at the end of the study period. 
116 
 
This shows that addition of Lycopene did not affect the hematological and biochemical 
parameters. 
The number of adverse events observed was less in patients receiving Lycopene 
as add on therapy compared to patients receiving Atorvastatin alone. All the Adverse 
Drug Reactions were categorized as possible under WHO causality assessment scale. 
According to the Modified Hartwig and Siegel severity assessment scale all the reactions 
reported was mild. This shows that Lycopene did not increase the occurrence of adverse 
events. 
As evidenced by earlier studies, our study has also modestly observed that 
addition of lycopene to Atorvastatin significantly reduced the total cholesterol and LDL 
cholesterol levels. Addition of lycopene to atorvastatin has not produced changes in 
hematological, biochemical parameters and adverse drug effect is also mild and thus 
resulted in significant improvement in the quality of life.  
So whether, lycopene may be considered as an alternative to low dose statins or it 
can be used in combination with low dose statins without side effects in patients with 
slightly elevated cholesterol levels or whether it can be used as an antioxidant per se 
requires study with a longer duration. 
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CONCLUSION 
From our study, we can conclude that  
1. Lycopene as add on therapy to Atorvastatin is effective in reducing lipid levels. 
2. Lycopene is well tolerated. 
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APPENDIX - 1 
LIST OF ABBREVIATIONS USED 
CVD   -  Cardio Vascular Disease 
CHD   -   Coronary Heart Disease 
LDL-C  -  Low Density Lipoprotein Cholesterol 
VLDL-C  -  Very Low Density Lipoprotein Cholesterol 
IDL-C   - Intermediate Density Lipoprotein Cholesterol 
HDL-C  -  High Density Lipoprotein Cholesterol 
LPL   -  Lipoprotein Lipase 
ACAT   - Acyl CoA Cholesterol Acyltransferase 
SREBP  -  Sterol Regulatory Element Binding Protein  
CETP   - Cholesteryl ester transfer protein 
LCAT   - Lecithin Cholesterol Acyl Tranferase 
PPAR   - Peroxisome Proliferator Activated Receptor 
AHA   - American Heart Association 
HMG-CoA  - 3-Hydroxyl-3-methylglutarylcoenzyme A 
VCAM-1  - Vascular cell adhesion molecule-1 
ROS   -   Reactive Oxygen Species 
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APPENDIX – 2 
 
CASE REPORT FORM 
A  PROSPECTIVE, RANDOMIZED, OPEN LABEL, COMPARATIVE STUDY OF 
ATORVASTATIN ALONE AND ATORVASTATIN WITH LYCOPENE IN PATIENTS WITH 
HYPERLIPIDAEMIA ATTENDING TERTIARY CARE HOSPITAL 
 
PATIENT DEMOGRAPHY: 
 
NAME             :          
AGE/SEX        :                                                                         
PLACE    : 
OP No    :     
OCCUPATION : 
ADDRESS  : 
 
 
CONTACT NUMBER:     
                                             
DIAGNOSIS     :   
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S.No Inclusion criteria Yes No Exclusion criteria Yes No 
1. 25-60 years   Triglycerides > 250 
mg/dl. 
 
  
2. Total cholesterol 
level between 
200-250 mg/dl 
  Total cholesterol: HDL 
ratio > 4.5. 
  
3. HT/DM   H/o allergy or 
intolerance to lycopene 
  
4. Patients willing to 
give written 
informed consent 
  Pregnant and lactating 
women 
  
5.    Patient with chronic 
systemic disease 
  
 
SUBJECT:               INCLUDED                           EXCLUDED 
 
RANDOMISATION: CONTROL GROUP                STUDY GROUP 
 
REASON IF EXCLUDED: 
 
SIGNATURE OF PRINCIPAL INVESTIGATOR: 
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Medical history: 
 
VITAL SIGNS: 
VISITS VISIT 1 VISIT 2 VISIT 3 VISIT 4 VISIT 5 
Pulse rate      
BP      
Temperature      
General/systemic 
examination 
     
 
INVESTIGATIONS: 
Hematology 
Hb 
 
0 WEEKS 
 
8 WEEKS 
TC   
DC   
ESR   
Platelet   
Biochemistry 
Blood sugar 
  
Blood urea   
Serum creatinine   
SGOT   
SGPT   
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Lipid profile: 
Total cholesterol 
0 WEEKS 4 WEEKS 8 WEEKS 
   
HDL cholesterol    
Triglycerides    
LDL-C=[TC-HDL-VLDL]     
VLDL = TG/5     
     
   
ADVERSE EFFECTS: 
 
S.No 
 
ADVERSE EVENTS 
 
START DATE 
 
STOP DATE 
 
TREATMENT 
GIVEN 
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TRIAL CHECK LIST 
 
 
 
Particulars 
 
Screening 
&   
Baseline 
       
 
  Visit  1 
  
 
 
    Visit 2 
 
 
 
    Visit 3 
 
 
 
     Visit 4 
 
     Visit 5 
 
 
Days 
 
 
         
 
0 
 
2 weeks 
 
4 weeks 
 
6 weeks 
 
8 weeks 
Informed 
Consent 
 
  
    
Randomization 
 
  
    
Patient 
Demography 
  
    
Physical & 
Clinical 
examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood pressure 
 
 
 
 
 
 
 
 
 
 
 
 
TC,DC, ESR, 
Hb% 
 
 
 
    
 
 
Lipid profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
SGOT, SGPT 
  
 
 
   
 
Blood Sugar  
 
 
 
  
 
  
 
Blood urea       
Serum 
creatinine 
  
    
Urine analysis 
 
 
 
    
 
ECG 
 
 
 
  
 
  
 
Dispense 
Study   
Medication 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse Drug 
Event 
Monitoring 
 
 
 
 
 
 
 
 
 
 
 
 
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APPENDIX - 3 
INFORMED CONSENT FORM 
Title:    “A Prospective, Randomized, Open label, Comparative study of 
Atorvastatin alone and Atorvastatin with Lycopene in patients with 
Hyperlipidaemia Attending Tertiary care Hospital‖ 
Name of the Participant: 
 
 
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am over 
18 years of age and, exercising my free power of choice, hereby give my consent to be 
included as a participant in this study. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out of the study at any time without having to 
give any reasonand this will not affect my future treatment in this hospital.  
6. I hereby give permission to the investigators to release the information obtained 
from me as resultof participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC.Iunderstand that they are publicly presented. 
7. I have understand that my identity will be kept confidential if my data are 
publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. 
By signingthis consent form I attest that the information given in this document has been 
clearly explained to meand understood by me, I will be given a copy of this consent 
document. 
 
 
1.Name and signature / thumb impression of the participant (or legal representative if 
participantincompetent) 
 
Name ___________________  Signature_________________ Date_______ 
 
 
2.Name and Signature of impartial witness (required for illiterate patients): 
 
Name ______________________ Signature_________________ Date_______ 
 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _____________________ Signature_________________ Date_______ 
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APPENDIX - 4 
INFORMATION TO PARTICIPANTS 
 
Title:    “A Prospective, Randomized, Open label, Comparative study of 
Atorvastatin alone and Atorvastatin with Lycopene in patients with 
Hyperlipidaemia Attending Tertiary care Hospital‖ 
Principal Investigator:  
Name of Participant: 
This study is being conducted in Hypertension OPD at Rajiv Gandhi Govt. General 
Hospital, Chennai. You are invited to take part in this study. The information in this 
document is meant to help you decide whether or not to take part. Please feel free to ask if 
you have any queries or concerns. 
The purpose of this study 
Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis-induced 
conditions such as coronary heart disease (CHD), ischemic cerebrovascular disease, and 
peripheral vascular disease.  Atherosclerosis remains the major cause of increase in 
morbidity or mortality in a majority of middle-aged or older adults and account for about 
one-third of all deaths of persons in this age range . Lycopene, a most predominant 
carotenoid in human plasma and a natural pigment synthesized by plants and is one of 
the most potent and most effective antioxidant in protecting the lipid peroxidation of the 
liposomal membrane, lipid metabolism, and corresponding development of 
atherosclerosis.Thus we want to test the efficacy and safety of treatment with Lycopene 
in reducing lipid levels. 
We have obtained permission from the Institutional Ethics Committee.  
The study design 
All patients in the study will be divided into 2 groups A & B. You will be 
assigned to either of the groups. Group A will receive standard treatment & Group B will 
receive standard treatment + Lycopene. 
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Study Procedures 
The study involves evaluation of decrease in lipid levels. The planned scheduled 
visits involve visits at 2
nd
, 4
th
, 6
th
, 8
th
 week after your initial visit. You will be required to 
visit the hospital 5 times during the study. At each visit, the study physician will examine 
you. Blood tests will be carried out thrice during the study (at screening , 4
th
 and at the 
end of study) and total of about 40 ml blood will be collected. These tests are essential to 
monitor your condition, and to assess the safety and efficacy of the treatment given to 
you. 
In addition, if you notice any adverse events, you have to report it. You will be 
required to return unused study medicines when you report for your scheduled visits. 
This will enable correct assessment of the study results. 
Possible benefits to you – Lycopene along with standard treatment will cause reduction 
in lipid levels. 
 Possible benefits to other people - The results of the research may provide benefits to 
the society in terms of advancement of medical knowledge and/or therapeutic benefit to 
future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and your 
medical history). By signing this document, you will be allowing the research team 
investigators, other study personnel, and Institutional Ethics Committee to view your 
data, if required.The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
Your decision to not participate in the study affect you 
Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken care of  
and you will not loose any benefits to which you are entitled.  
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Can you decide to stop participating in the study once you start 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving any 
reasons. However, it is advisable that you talk to the research team prior to stopping the 
treatment/discontinuing of procedures etc. 
The expenditure for the treatment and investigation for this study will not be collected 
from you. 
 
 
Signature of Investigator                                                 Signature of Participant   
Date                                                                                     Date   
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